RCA HGB-208 Pushback Seen as 'Modest Stumble', Roth Capital Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BMO Capital Sees 'Deminimus Impact' on bluebird bio (BLUE) Valuation Even If Launch Delayed
June 10, 2015 8:06 AM EDTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and $200 price target on bluebird bio (NASDAQ: BLUE) after the company announced late yesterday that the NIH's Recombinant DNA Advisory Committee (RAC) has recommended delaying initiation of the HGB-208 pediatric study protocol by 1-2... More
bluebird bio (BLUE) Say NIH's RAC Recommends Delay of HGB-208 Pediatric Study for 1-2 Years
June 9, 2015 6:43 PM EDTbluebird bio, Inc. (Nasdaq: BLUE) announced today the completion of the National Institutes of Health (NIH) Recombinant DNA Advisory Committees (RAC) public review of the HGB-208 pediatric study protocol for bluebird bios LentiGlobin BB305 product candidate in beta-thalassemia major. The RAC recommendation was to delay initiation of the study in the United States for one to two years. This recommendation has no effect on the HGB-207 protocol plan.
We appreciate the recommendations from the RAC members regarding the HGB-208 pediatric study protocol, said David Davidson, M.D., chief medical officer. We... More
Roth Capital Reiterates Bullish View on bluebird bio (BLUE) Ahead of EHA Data
June 9, 2015 9:01 AM EDTRoth Capital analyst Debjit Chattopadhyay highlighted bluebird bio (NASDAQ: BLUE) ahead of EHA data on June 13th.
Chattopadhyay commented, "Continued transfusion independence in beta-thalassemia and total anti-sickling hemoglobin in excess of 40% (well above the 30% threshold), accompanied by robust clinical benefit (elimination of hospitalizations)... More
